Beneficial Effects of CNCM I-745 on Clinical Disorders Associated with Intestinal Barrier Disruption

Overview

Journal Clin Exp Gastroenterol

Publisher Dove Medical Press

Specialty Gastroenterology

Date 2019 Feb 27

PMID 30804678

Citations 24

Authors

Chloe Terciolo

Michel Dapoigny

Frederic Andre

Affiliations

Soon will be listed here.

Abstract

Intestinal barrier defects lead to "leaky gut syndrome", defined as an increase in intestinal permeability that allows the passage of luminal content into intestinal tissue and the bloodstream. Such a compromised intestinal barrier is the main factor underlying the pathogenesis of inflammatory bowel disease, but also commonly occurs in various systemic diseases such as viral infections and metabolic syndrome. The non-pathogenic yeast CNCM I-745 has demonstrated its effectiveness as a probiotic in the prevention and treatment of antibiotic-associated, infectious and functional diarrhea. Via multiple mechanisms of action implicated in intestinal barrier function, has beneficial effects on altered intestinal microbiota and epithelial barrier defects in different pathologies. The well-studied probiotic yeast plays a crucial role in the preservation and/or restoration of intestinal barrier function in multiple disorders. This could be of major interest in diseases characterized by alterations in intestinal barrier function.

Citing Articles

Mechanism of Action and Beneficial Effects of Probiotics in Amateur and Professional Athletes.

Nami Y, Barghi A, Shahgolzari M, Salehian M, Haghshenas B Food Sci Nutr. 2025; 13(1):e4658.

PMID: 39803224 PMC: 11717059. DOI: 10.1002/fsn3.4658.

Oral Treatment with Saccharomyces cerevisiae CNCM I-3856 Mitigates the Inflammatory Response Experimentally Induced by Salmonella enterica subsp. enterica Serovar Typhimurium in Mice.

Campos L, Oliveira S, Amaral M, Gallotti B, Oliveira A, Arantes R Probiotics Antimicrob Proteins. 2024; .

PMID: 39243351 DOI: 10.1007/s12602-024-10359-4.

The supplementation of female dogs with live yeast var. CNCM I-1079 acts as gut stabilizer at whelping and modulates immunometabolic phenotype of the puppies.

Garrigues Q, Mugnier A, Chastant S, Sicard F, Martin J, Svilar L Front Nutr. 2024; 11:1366256.

PMID: 38680531 PMC: 11048480. DOI: 10.3389/fnut.2024.1366256.

The Anti-Inflammatory and Curative Exponent of Probiotics: A Comprehensive and Authentic Ingredient for the Sustained Functioning of Major Human Organs.

Virk M, Virk M, He Y, Tufail T, Gul M, Qayum A Nutrients. 2024; 16(4).

PMID: 38398870 PMC: 10893534. DOI: 10.3390/nu16040546.

The Networked Interaction between Probiotics and Intestine in Health and Disease: A Promising Success Story.

Skoufou M, Tsigalou C, Vradelis S, Bezirtzoglou E Microorganisms. 2024; 12(1).

PMID: 38258020 PMC: 10818559. DOI: 10.3390/microorganisms12010194.

References

Cosnes J, Gower-Rousseau C, Seksik P, Cortot A . Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011; 140(6):1785-94. DOI: 10.1053/j.gastro.2011.01.055. View

Freter R, Brickner H, Fekete J, Vickerman M, Carey K . Survival and implantation of Escherichia coli in the intestinal tract. Infect Immun. 1983; 39(2):686-703. PMC: 348005. DOI: 10.1128/iai.39.2.686-703.1983. View

Leiva-Gea I, Sanchez-Alcoholado L, Martin-Tejedor B, Castellano-Castillo D, Moreno-Indias I, Urda-Cardona A . Gut Microbiota Differs in Composition and Functionality Between Children With Type 1 Diabetes and MODY2 and Healthy Control Subjects: A Case-Control Study. Diabetes Care. 2018; 41(11):2385-2395. DOI: 10.2337/dc18-0253. View

Ukena S, Singh A, Dringenberg U, Engelhardt R, Seidler U, Hansen W . Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. PLoS One. 2007; 2(12):e1308. PMC: 2110898. DOI: 10.1371/journal.pone.0001308. View

Buts J, Bernasconi P, Vaerman J, Dive C . Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. Dig Dis Sci. 1990; 35(2):251-6. DOI: 10.1007/BF01536771. View

Czerucka D, Nano J, Bernasconi P, Rampal P . [Response to cholera toxin of 2 epithelial intestinal cell lines. Effect of Saccharomyces boulardii]. Gastroenterol Clin Biol. 1989; 13(4):383-7. View

Capaldo C, Nusrat A . Cytokine regulation of tight junctions. Biochim Biophys Acta. 2008; 1788(4):864-71. PMC: 2699410. DOI: 10.1016/j.bbamem.2008.08.027. View

Ajslev T, Andersen C, Gamborg M, Sorensen T, Jess T . Childhood overweight after establishment of the gut microbiota: the role of delivery mode, pre-pregnancy weight and early administration of antibiotics. Int J Obes (Lond). 2011; 35(4):522-9. DOI: 10.1038/ijo.2011.27. View

Swidsinski A, Loening-Baucke V, Kirsch S, Doerffel Y . [Functional biostructure of colonic microbiota (central fermenting area, germinal stock area and separating mucus layer) in healthy subjects and patients with diarrhea treated with Saccharomyces boulardii]. Gastroenterol Clin Biol. 2010; 34 Suppl 1:S79-92. DOI: 10.1016/S0399-8320(10)70025-7. View

10.

Jandhyala S, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Reddy D . Role of the normal gut microbiota. World J Gastroenterol. 2015; 21(29):8787-803. PMC: 4528021. DOI: 10.3748/wjg.v21.i29.8787. View

11.

Tamura A, Hayashi H, Imasato M, Yamazaki Y, Hagiwara A, Wada M . Loss of claudin-15, but not claudin-2, causes Na+ deficiency and glucose malabsorption in mouse small intestine. Gastroenterology. 2010; 140(3):913-23. DOI: 10.1053/j.gastro.2010.08.006. View

12.

Delzenne N, Neyrinck A, Cani P . Gut microbiota and metabolic disorders: How prebiotic can work?. Br J Nutr. 2013; 109 Suppl 2:S81-5. DOI: 10.1017/S0007114512004047. View

13.

Sjogren Y, Tomicic S, Lundberg A, Bottcher M, Bjorksten B, Sverremark-Ekstrom E . Influence of early gut microbiota on the maturation of childhood mucosal and systemic immune responses. Clin Exp Allergy. 2009; 39(12):1842-51. DOI: 10.1111/j.1365-2222.2009.03326.x. View

14.

Bin Z, Ya-Zheng X, Zhao-Hui D, Bo C, Li-Rong J, Vandenplas Y . The Efficacy of Saccharomyces boulardii CNCM I-745 in Addition to Standard Helicobacter pylori Eradication Treatment in Children. Pediatr Gastroenterol Hepatol Nutr. 2015; 18(1):17-22. PMC: 4391996. DOI: 10.5223/pghn.2015.18.1.17. View

15.

Zhang Y, Li S, Gan R, Zhou T, Xu D, Li H . Impacts of gut bacteria on human health and diseases. Int J Mol Sci. 2015; 16(4):7493-519. PMC: 4425030. DOI: 10.3390/ijms16047493. View

16.

Terciolo C, Dobric A, Ouaissi M, Siret C, Breuzard G, Silvy F . Saccharomyces boulardii CNCM I-745 Restores intestinal Barrier Integrity by Regulation of E-cadherin Recycling. J Crohns Colitis. 2017; 11(8):999-1010. DOI: 10.1093/ecco-jcc/jjx030. View

17.

Chang B, Sang L, Wang Y, Tong J, Wang B . The role of FoxO4 in the relationship between alcohol-induced intestinal barrier dysfunction and liver injury. Int J Mol Med. 2013; 31(3):569-76. DOI: 10.3892/ijmm.2013.1229. View

18.

Li X, Atkinson M . The role for gut permeability in the pathogenesis of type 1 diabetes--a solid or leaky concept?. Pediatr Diabetes. 2015; 16(7):485-92. PMC: 4638168. DOI: 10.1111/pedi.12305. View

19.

Schnabl B, Brenner D . Interactions between the intestinal microbiome and liver diseases. Gastroenterology. 2014; 146(6):1513-24. PMC: 3996054. DOI: 10.1053/j.gastro.2014.01.020. View

20.

Martins F, Vieira A, Elian S, Arantes R, Tiago F, Sousa L . Inhibition of tissue inflammation and bacterial translocation as one of the protective mechanisms of Saccharomyces boulardii against Salmonella infection in mice. Microbes Infect. 2013; 15(4):270-9. DOI: 10.1016/j.micinf.2012.12.007. View